SEC Form 4 · accession 0001104659-15-079666

Vitae Pharmaceuticals, Inc · VTAE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).

Reporting owner

Officer — Chief Science Officer

Period of report

Nov 13, 2015

Accepted (ET)

Nov 17, 2015 · 4:30 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001157602

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Nov 13, 2015	M	65,089	$3.91	A	65,089	D
Common Stock	Nov 13, 2015	M	13,695	$3.91	A	78,784	D
Common Stock	Nov 13, 2015	M	6,773	$6.90	A	85,557	D
Common Stock	Nov 16, 2015	M	15,000	$3.91	A	100,557	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to Buy)^F1	$3.91	Nov 13, 2015	M	65,089	D	—	Mar 25, 2018	Common Stock	65,089	102,301	D
Employee Stock Option (Right to Buy)^F2	$3.91	Nov 13, 2015	M	13,695	D	—	Jan 20, 2019	Common Stock	13,695	0	D
Employee Stock Option (Right to Buy)^F3	$6.90	Nov 13, 2015	M	6,773	D	—	Mar 23, 2020	Common Stock	6,773	0	D
Employee Stock Option (Right to Buy)^F1	$3.91	Nov 16, 2015	M	15,000	D	—	Mar 25, 2018	Common Stock	15,000	87,301	D

F1This option vested over four years of service following February 25, 2008, with 25% vesting upon completion of one year of service and in 36 equal monthly installments thereafter.
F2This option vested in equal monthly installments over 12 months of service following March 15, 2009.
F3This option vested in equal monthly installments over 12 months of service following March 15, 2010.